Citi is adding an “upside 90-day catalyst watch” on Arcturus Therapeutics (ARCT) ahead of the Cystic Fibrosis catalyst expected in early Q3. The firm highlights potential upside on a Phase 2 readout from the company’s CF program and keeps an Overweight rating and $47 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Buy Rating Affirmed Amid Promising OTC Developments and Upcoming CF Catalyst
- Promising Potential of Arcturus Therapeutics’ mRNA Therapies Drives Buy Rating
- Arcturus Therapeutics Announces Positive Phase 2 Results
- Arcturus announces ‘positive’ interim Phase 2 multiple dose data for ARCT-810
- Positive Outlook on Arcturus Therapeutics Driven by Promising mRNA Advancements and Strategic Developments